<div id="readability-page-1"><p>Relay Therapeutics received a Buy rating and a  price target from Wells Fargo analyst Eva Fortea Verdejo today.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Fortea Verdejo is a 5-star analyst with an average return of <span>61.2%</span> and an 89.47% success rate. Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Zymeworks, Merus, and Xencor.</p> <p>Currently, the analyst consensus on Relay Therapeutics is a Strong Buy with an average price target of $14.80.</p></div>

RLAY

<p>Wells Fargo analyst Eva Fortea Verdejo has given Relay Therapeutics a Buy rating and set a price target. Fortea Verdejo, a 5-star analyst with a 61.2% average return, focuses on the Healthcare sector. The analyst consensus for Relay Therapeutics is a Strong Buy with an average price target of $14.80.</p>

Positive Report for Relay Therapeutics (RLAY) from Wells Fargo